Literature DB >> 26777601

Low sodium status in cystic fibrosis-as assessed by calculating fractional Na(+) excretion-is associated with decreased growth parameters.

Christiane Knepper1, Helmut Ellemunter2, Johannes Eder2, Katharina Niedermayr2, Bettina Haerter3, Philipp Hofer4, Sabine Scholl-Bürgi1, Thomas Müller1, Peter Heinz-Erian5.   

Abstract

BACKGROUND: In CF infants, normonatremic Na(+) depletion (NNaD), identified by fractional Na(+) excretion (FENa) values <0.5%, was recently linked to impaired growth. Our paper investigates the relationship between FENa and growth in CF children >2years.
METHODS: FENa values were calculated in 35 CF and 24 control children, and tested for correlations with z-scores for weight, height and BMI.
RESULTS: All CF children and controls had normal plasma Na(+) concentrations. A total of 25 of 35 (71.4%) CF patients had decreased FENa values <0.5% (group I). FENa results of 10 CF patients (group II) and 23/24 controls (group III) were normal. In Na(+)-depleted CF children, compared to normal controls, mean z-scores for weight (-0.18±0.87 vs +1.03±0.57, p<0.001), height (-0.06±0.89 vs +0.53±0.72, p=0.009) and BMI (-0.22±0.87 vs +1.00±1.06, p<0.001) were significantly reduced. Also, we found positive correlations between FENa values and z-scores for weight (r=0.521), height (r=0.292) and BMI (r=0.468), respectively.
CONCLUSION: NNaD may contribute to poor growth in CF.
Copyright © 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Fractional sodium excretion; Growth retardation; Normonatremic sodium depletion

Mesh:

Substances:

Year:  2016        PMID: 26777601     DOI: 10.1016/j.jcf.2015.12.010

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  6 in total

1.  The fractional excretion of sodium in patients with cystic fibrosis treated with oral sodium chloride.

Authors:  Majid Keivanfar; Sosan Daris; Mohsen Reisi; Mehryar Mehrkesh
Journal:  Am J Clin Exp Urol       Date:  2020-12-15

2.  Evaluating sedative effects of dexmedetomidine and morphine in the patients with opioid use disorder undergoing cataract surgery.

Authors:  Dariush Moradi Farsani; Keyvan Ghadimi; Raana Abrishamkar; Kamran Montazeri; Alireza Peyman
Journal:  Am J Clin Exp Immunol       Date:  2021-02-15

Review 3.  Cystic fibrosis liver disease: A condition in need of structured transition and continuity of care.

Authors:  Julian Hercun; Fernando Alvarez; Catherine Vincent; Marc Bilodeau
Journal:  Can Liver J       Date:  2019-08-27

4.  The association between Sodium Urinary Discharge (FENa) and growth parameters in pediatrics with cystic fibrosis.

Authors:  Mohsen Reisi; Majid Keivanfar; Mahboobe Rezaie; Silva Hovsepian
Journal:  Am J Clin Exp Urol       Date:  2022-08-15

5.  REAL-world clinical effectiveness of ivacaftor therapy in the first 24 months in two infants with cystic fibrosis and different gating mutations-A case report.

Authors:  Teresa Fuchs; Dorothea Appelt; Katharina Niedermayr; Helmut Ellemunter
Journal:  Clin Case Rep       Date:  2022-02-10

Review 6.  Is the ENaC Dysregulation in CF an Effect of Protein-Lipid Interaction in the Membranes?

Authors:  Birgitta Strandvik
Journal:  Int J Mol Sci       Date:  2021-03-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.